Global patient monitoring devices market estimated to reach $22B by 2018

Laura Pedulli | | Health Exec | Precision Medicine

The global patient monitoring devices market is estimated to reach $22.1 billion by 2018 at a CAGR of 5.5 percent, according to a report from MarketsandMarkets.

The market—divided into segments including hemodynamic, neurology, cardiac, respiratory, fetal and neonatal, multiparameter, remote patient monitors, temperature and weight management monitors— is growing thanks to rising numbers of the geriatric population, rising incidences of lifestyle disease, and ease-of-use and portability of remote monitoring devices. The leading market segment is cardiac monitoring, according to the research firm.

North America commanded the largest share in the patient monitoring devices market in 2013. Europe had the second largest share, but this is expected to taper out during the forecast period. However, growth is expected in India and China due to the improved purchasing power of the rising middle class.

Learn more here.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.